title: Coexistence of psoriasis vulgaris and bullous disorders.
authors.forename: S
authors.initials: S
authors.lastname: Aytekin
authors.forename: H S
authors.initials: HS
authors.lastname: Inalöz
authors.forename: M
authors.initials: M
authors.lastname: Harman
authors.forename: S
authors.initials: S
authors.lastname: Akdeniz
authors.forename: E
authors.initials: E
authors.lastname: Deveci
authors.forename: S S
authors.initials: SS
authors.lastname: Inalöz
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D003874:Dermatitis Herpetiformis / Q000150:complications* / Q000188:drug therapy; D003937:Diagnosis, Differential; D019085:Fluorescent Antibody Technique, Direct; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D008297:Male; D008875:Middle Aged; D010392:Pemphigus / Q000150:complications* / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D011565:Psoriasis / Q000150:complications*
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003622:Dapsone; D011239:Prednisolone